Industry leaders at CPHI Frankfurt this week discussed embracing technologies such as automation, AI, and innovative manufacturing platforms all in an effort to improve efficiency, quality, scalability and sustainability in pharmaceutical production and development

As part of a three-part feature with Manufacturing Chemist, our Chief Strategy Officer, Matthew Paterson, shared: "As a CDMO partner, we are increasingly able to support clients that are looking for US-based drug product manufacturing support. The ongoing discussions and incentives to bring pharmaceutical manufacturing back onshore in the US has sparked more attention in services available from our Philadelphia-based facilities."

CDMO facilities in Philadelphia have been part of Quotient Sciences’ sites for nearly 10 years. These facilities feature drug product formulation and manufacturing capabilities for all stages of development, from clinical to commercial scale, and are part of executing integrated Translational Pharmaceutics programs for US-based clients.

"More companies are exploring their options from US-based providers, and we’re well-positioned to assist clients by offering services from both our UK and US locations." he says.

The article features Quotient Sciences contributions along with other industry experts, highlighting the challenges and solutions involved in process optimisation, technology transfer and the adoption of digital and sustainable manufacturing methods. Read the three-part series on the Manufacturing Chemist website:

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part I)

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part II)

Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)

Quotient Sciences has been recognized as a 2025 CDMO Leadership Awards Europe category winner and juried award recipient at an award ceremony held during CPhI Frankfurt this week in Frankfurt, Germany.

The CDMO Leadership Awards recognize the best contract development and manufacturing organizations (CDMOs). For the first time, these awards recognize CDMOs with a presence in Europe and the UK. 

Quotient Sciences has won in the categories of Small Molecule Dosage Form and Best European Innovative CDMO, a Jury Award Category.

Derived from proprietary data by Life Science Connect and research by Orientation Marketing, CDMO buyers from across biopharma evaluated the partners they worked with in the past 24 months. A blended scoring system based on Net Promoter Scores and Best-in-Class Rankings determines the finalists and champions.

“Outsourced Pharma is proud to host our CDMO Leadership Awards in Europe for the first time in our history of over a decade. The 2025 CDMO Leadership Awards Europe is a well-deserved recognition to European organizations that have demonstrated excellence in contract development and manufacturing.” said Louis Garguilo, Chief Editor, Outsourced Pharma

About the CDMO Leadership Awards

The CDMO Leadership Awards are presented by Outsourced Pharma and Life Science Connect. Winners are selected based on primary research conducted by Orientation Marketing, reflecting direct feedback from biopharmaceutical professionals who have recently partnered with CDMOs. The awards recognize contract development and manufacturing organizations that deliver excellence in quality, capabilities, expertise, reliability, compatibility, and service. Learn more at www.cmoleadershipawards.com.

About Life Science Connect

Life Science Connect is a network of trusted online communities, including Clinical Leader, Outsourced Pharma, Bioprocess Online, Cell & Gene, and others, dedicated to helping industry professionals make informed decisions and build valuable partnerships. Through expert editorial content and innovative commercial solutions, LSC connects biopharma professionals with suppliers who can help advance development and manufacturing programs.

We are proud to announce that Quotient Sciences’ commitment to set science-based targets through the Science Based Targets initiative (SBTi) has been officially approved. Our participation is reflected as part of the SBTi Target Dashboard, along with our pledge to develop near-term greenhouse gas (GHG) emissions reduction targets and submit them for validation.  

This milestone marks a significant step forward in our sustainability journey and demonstrates our dedication to tackling climate change in line with the latest climate science.

SBTi is a corporate climate action organization that provides companies with a clear pathway to reduce greenhouse gas emissions in line with the goals of the Paris Agreement, limiting global warming to well below 2°C above pre-industrial levels, and pursuing efforts to limit warming to 1.5°C.

Quotient Sciences joins the growing list of over 11,000 global organizations with targets or commitments for lowering GHG emissions.

Building on our ESG progress

Our SBTi commitment is a natural extension of our ESG strategy, reinforcing our pledge to transparency, continuous improvement, and stakeholder trust. We will now work to develop and submit our near-term, science-based targets and submit them to SBTi for validation. Our two-year milestones will include:  

• Setting a science-based carbon reduction target, building on the data foundations laid in 2024
• Continuing to broaden the My Green Lab Ambassador Program and expand education outreach programs at each of our sites
• Enhancing supplier collaboration to drive sustainability across our value chain
• Increasing transparency and performance through ongoing ESG reporting and stakeholder engagement

Our SBTi commitment builds directly on the progress outlined in our 2024 ESG Report, which details our efforts to enhance transparency, accountability, and impact across environmental, social, and governance priorities.  

“ESG is not a standalone initiative, but principles that are woven into the fabric of who we are and how we operate each day.” commented Quotient Sciences’ CEO, Thierry Van Nieuwenhove.

As we look ahead, we remain focused on delivering long-term value for our partners, colleagues, and communities, helping to build a more sustainable, inclusive, and resilient future.  

Read our full 2024 ESG report

Dr. Andrew Parker, Dr. Sandeep Kumar, and John McDermott featured in Drug Development & Delivery's article, "PRECLINICAL SCREENING PLATFORM - From Preclinical Screening to Clinical Optimization: Accelerating Poorly Soluble Drug Development".

It’s well understood most drugs emerging from discovery pipelines possess poor aqueous solubility and/or low permeabil­ity, providing barriers to absorption and bioavailability. Enhancing absorption is therefore a cornerstone of formulation science, di­rectly impacting oral bioavailability and therapeutic index.

When choosing a CDMO partner, finding one with experi­ence in the development of enabled formulation systems, such as amorphous solid dispersions and lipidic systems, is critical to advancing molecules that have poor solubility. Additionally, an “end-to-end” integrated service philosophy, in which all elements of drug development can be procured through a single vendor with capabilities and experience to pivot to the respective needs of a drug’s biopharmaceutic properties, can further accelerate development at all stages.

In the preclinical phase, establishing formulations capable of achieving sufficient drug solubility to probe toxicology is key. Here, Quotient Sciences, applies a systematic, data-driven screening platform evaluating solubility-enhancement ap­proaches to direct the toxicology formulation. As a drug ap­proaches a first-in-human (FIH) trial, the Quotient Sciences Translational Pharmaceutics® platform enables development teams to minimize investment in GMP drug product manufactur­ing by making drug products on-demand. This allows the devel­opment team to reduce supply chain complexity and rapidly apply enabled formulations in the trial to ensure drug exposure. Finally, the Translational Pharmaceutics platform® can be applied to fur­ther optimize drug product formulations using clinical data fol­lowing Phase 1 studies.

In one case, Quotient Sciences successfully developed an amorphous solid dispersion of a poorly soluble molecule using spray drying. The drug product was used in the first-in-human study of an oral therapy intended for the treatment of amy­otrophic lateral sclerosis (ALS). The randomized, placebo- controlled Phase 1 trial evaluated safety, tolerability, pharmaco­kinetics (PK), pharmacodynamics (PD), and impact of food in healthy volunteers. Among the three formulations tested in this trial, the spray-dried version showed superior performance and was selected for further development. This study highlights how an integrated approach and adaptive design accelerates early phase development and de-risks formulation decisions using real-time clinical data.

Read the full article on Drug Development & Delivery's website here.